Cargando...
Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion accounts for 3%-5% of non-small cell lung cancer (NSCLC) patients. With the in-depth study of the EML4-ALK driver gene, ALK inhibitors represented by crizotinib have been gradually developed and applied in...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Chinês |
| Publicado: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-11-01
|
| Colección: | Chinese Journal of Lung Cancer |
| Materias: | |
| Acceso en línea: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.44 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|